54185-4 |
Caspofungin |
Susc |
Isolate |
Pt |
OrdQn |
Gradient strip |
|
ACTIVE |
Caspofungin [Susceptibility] by Gradient strip |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54185-4 |
|
Gradient strip |
|
|
Both |
|
|
|
0 |
Caspofungin Islt Grad strip |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Epsilometer; Estrip; E-strip; Grad strip; ID; Infectious Disease; InfectiousDisease; Islt; Isol; MIC; Minimum inhibitory concentration; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.56 |
2.27 |
|
|
|
|
|
|
|
|
|
|
Feb 2016-removed "E-test" from the short and long names because the "ETEST" name is trademarked |
0 |
54186-2 |
Posaconazole |
Susc |
Isolate |
Pt |
OrdQn |
Gradient strip |
|
ACTIVE |
Posaconazole [Susceptibility] by Gradient strip |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54186-2 |
|
Gradient strip |
|
|
Both |
|
|
|
0 |
Posaconazole Islt Grad strip |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Epsilometer; Estrip; E-strip; Grad strip; ID; Infectious Disease; InfectiousDisease; Islt; Isol; MIC; Minimum inhibitory concentration; Noxafil; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.56 |
2.27 |
|
|
|
|
|
|
|
|
|
|
Feb 2016-removed "E-test" from the short and long names because the "ETEST" name is trademarked |
0 |
54187-0 |
Posaconazole |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Posaconazole [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54187-0 |
|
MIC |
|
|
Both |
|
|
|
0 |
Posaconazole Islt MIC |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; Noxafil; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.73 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54188-8 |
Posaconazole |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Posaconazole [Susceptibility] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54188-8 |
|
|
|
|
Both |
|
|
|
0 |
Posaconazole Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Noxafil; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54189-6 |
Posaconazole |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Posaconazole [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54189-6 |
|
Agar diffusion |
|
|
Both |
|
|
|
0 |
Posaconazole Islt KB |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Disk diffusion; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Noxafil; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
5419-7 |
CD104 |
ACnc |
WBC |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated CD104 cells/100 cells in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
5419-7 |
|
|
|
|
|
|
|
|
0 |
Deprecated CD104 WBC-aCnc |
|
|
|
|
|
Arbitrary concentration; Beta 4; Beta 4 integrin chain; Beta4; Beta-4 integrin; CELL MARKERS; Leukocytes; Point in time; QNT; Quan; Quant; Quantitative; Random; TSP-1180; tumor specific protein 180 antigen; WBCs; White blood cells |
2.69 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
54190-4 |
Temocillin |
Susc |
Isolate |
Pt |
OrdQn |
Gradient strip |
|
ACTIVE |
Temocillin [Susceptibility] by Gradient strip |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54190-4 |
|
Gradient strip |
|
|
Both |
|
|
|
0 |
Temocillin Islt Grad strip |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Epsilometer; Estrip; E-strip; Grad strip; ID; Infectious Disease; InfectiousDisease; Islt; Isol; MIC; Minimum inhibitory concentration; Nagaban; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Temopen |
2.56 |
2.27 |
|
|
|
|
|
|
|
|
|
|
Feb 2016-removed "E-test" from the short and long names because the "ETEST" name is trademarked |
0 |
54191-2 |
Cefotaxime+Sulbactam |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Cefotaxime+Sulbactam [Susceptibility] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54191-2 |
|
|
|
|
Both |
|
|
|
0 |
Cefotaxime+Sulbac Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Claforan; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Point in time; Random; Sulb; Sulbact; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54192-0 |
Cefotaxime+Sulbactam |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Cefotaxime+Sulbactam [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54192-0 |
|
MIC |
|
|
Both |
|
|
|
0 |
Cefotaxime+Sulbac Islt MIC |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Claforan; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; Point in time; Random; Sulb; Sulbact; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54193-8 |
Cefotaxime+Sulbactam |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Cefotaxime+Sulbactam [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54193-8 |
|
Agar diffusion |
|
|
Both |
|
|
|
0 |
Cefotaxime+Sulbac Islt KB |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Claforan; Disk diffusion; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Point in time; Random; Sulb; Sulbact; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54194-6 |
Mezlocillin+Sulbactam |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Mezlocillin+Sulbactam [Susceptibility] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54194-6 |
|
|
|
|
Both |
|
|
|
0 |
Mezlocillin+Sulbac Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Baypen; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Mezlin; Optocillin; Point in time; Random; Sulb; Sulbact; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54195-3 |
Mezlocillin+Sulbactam |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Mezlocillin+Sulbactam [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54195-3 |
|
MIC |
|
|
Both |
|
|
|
0 |
Mezlocillin+Sulbac Islt MIC |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Baypen; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Mezlin; Minimum inhibitory concentration; Optocillin; Point in time; Random; Sulb; Sulbact; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54196-1 |
Mezlocillin+Sulbactam |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Mezlocillin+Sulbactam [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54196-1 |
|
Agar diffusion |
|
|
Both |
|
|
|
0 |
Mezlocillin+Sulbac Islt KB |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Baypen; Disk diffusion; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Mezlin; Optocillin; Point in time; Random; Sulb; Sulbact; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54197-9 |
Piperacillin+Sulbactam |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Piperacillin+Sulbactam [Susceptibility] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54197-9 |
|
|
|
|
Both |
|
|
|
0 |
Piperacillin+Sulbac Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Piper; PIPJ; Pipracil; Point in time; Random; Sulb; Sulbact; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54198-7 |
Piperacillin+Sulbactam |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Piperacillin+Sulbactam [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54198-7 |
|
MIC |
|
|
Both |
|
|
|
0 |
Piperacillin+Sulbac Islt MIC |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; Piper; PIPJ; Pipracil; Point in time; Random; Sulb; Sulbact; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54199-5 |
Piperacillin+Sulbactam |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Piperacillin+Sulbactam [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54199-5 |
|
Agar diffusion |
|
|
Both |
|
|
|
0 |
Piperacillin+Sulbac Islt KB |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Disk diffusion; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Piper; PIPJ; Pipracil; Point in time; Random; Sulb; Sulbact; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
542-1 |
Mycobacterium sp |
Prid |
Wound |
Pt |
Nom |
Organism specific culture |
|
ACTIVE |
Mycobacterium sp identified in Wound by Organism specific culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
542-1 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
Mycobacterium Wnd Cult |
|
|
|
|
|
Acid Fast; Acid Fast Bacilli; Acid fast bacillus; AFB; C&S; Cult; Cultures; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Myco; Mycobact; Nominal; Point in time; Random; Spec; species; spp; Tuberculosis; Wnd |
2.78 |
1 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; |
0 |
5420-5 |
CD105 |
ACnc |
WBC |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated CD105 cells/100 cells in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
5420-5 |
|
|
|
|
|
|
|
|
0 |
Deprecated CD105 WBC-aCnc |
|
|
|
|
|
Arbitrary concentration; CELL MARKERS; Endoglin; Leukocytes; Point in time; QNT; Quan; Quant; Quantitative; Random; WBCs; White blood cells |
2.69 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
54200-1 |
Griseofulvin |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Griseofulvin [Susceptibility] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54200-1 |
|
|
|
|
Both |
|
|
|
0 |
Griseofulvin Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54201-9 |
Griseofulvin |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Griseofulvin [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54201-9 |
|
MIC |
|
|
Both |
|
|
|
0 |
Griseofulvin Islt MIC |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.73 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54202-7 |
Griseofulvin |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Griseofulvin [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54202-7 |
|
Agar diffusion |
|
|
Both |
|
|
|
0 |
Griseofulvin Islt KB |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Disk diffusion; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54203-5 |
Cefmenoxime |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Cefmenoxime [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54203-5 |
|
MIC |
|
|
Both |
|
|
|
0 |
Cefmenoxime Islt MIC |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Bestcall; Cefmax; Cefmenoxim; Cemix; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Tacef |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54204-3 |
Thiacetazone |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Thiacetazone [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
54204-3 |
|
MIC |
|
|
Both |
|
|
|
0 |
Thiacetazone Islt MIC |
|
|
|
N |
|
Amithiozone; ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Thioacetazone |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54205-0 |
Legionella pneumophila 7+8+9+10+11+12+13+14 Ab |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Legionella pneumophila 7+8+9+10+11+12+13+14 Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
< 64 (Titre) |
|
|
|
|
|
MICRO |
|
54205-0 |
|
|
|
|
Both |
|
|
|
0 |
L pneumo 7-14 Ab Titr Ser |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Chicago 8; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; L pneumo; L pneumo 7-14; L pneumo 7-14 Ab; L pneumo7; L pneumonphila; Legion; Legionela; Legionella pneumophila serogroup 7; Microbiology; Pneu; pneum; Pneumophilia; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
2.27 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
54206-8 |
Cytomegalovirus DNA |
LnCnc |
Ser/Plas |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Cytomegalovirus DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
log copies/mL |
|
|
|
|
|
|
MICRO |
|
54206-8 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
CMV DNA SerPl NAA+probe-Log# |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; CMV; Cytomegalo virus; Cytomgal; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; HHV-5; Human Herpesvirus-5; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Log NCNC; Log#; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Pl; Plasma; Plsm; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load |
2.73 |
2.27 |
|
|
|
|
|
|
|
{Log_copies}/mL |
|
|
|
0 |